Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price ...

Disclaimer: This is an AI-generated summary of a press ... M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron. “This is an exciting development in our obesity ...

The companies are seeking to enhance their competitive edge by boosting research velocity, fortifying data security and leveraging AI ... Regeneron to gain new insights that can aid in drug ...

Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid: Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administrat ...

This proprietary AI/ML platform and robust scientific methodology is the cornerstone of our business development efforts in oncology drug discovery and repurposing,” Vennare concluded. Not unlike ...

Regeneron and Sanofi (NASDAQ:SNY) are collaborating on the global development of this drug ... our conviction lies in the belief that some AI stocks hold greater promise for delivering higher ...

Sanofi is an R&D driven, AI-powered biopharma company committed ... to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid  Approval based on pivotal results showing improvements in sustained disease remission and ...

This isn’t about accelerating drug development. That’s a public ... What happens when Regeneron partners with AI companies to model disease outcomes based on your code? What happens when ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use co ...

This isn’t about accelerating drug development. That’s a public relations veneer ... And let’s not pretend this is the end of the road. What happens when Regeneron partners with AI companies to model ...

The strategic move is aimed at integrating automated, high-throughput gene synthesis into Regeneron's in-house laboratories.